Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT01128452
- Locations
- 🇺🇸
Evotec Study Site 1, Baltimore, Maryland, United States
🇺🇸Evotec Study Site 12, Houston, Texas, United States
🇺🇸Evotec Study Site 2, Oak Brook, Illinois, United States
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
Phase 2
Terminated
- Conditions
- Depression
- Interventions
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01114698
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
Phase 3
Terminated
- Conditions
- Community-Acquired InfectionsNosocomial InfectionPneumonia, Ventilator-AssociatedPneumonia, Bacterial
- Interventions
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01110421
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections
Phase 3
Terminated
- Conditions
- Complicated Urinary Tract Infections or Pyelonephritis
- Interventions
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT01110408
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
Phase 3
Terminated
- Conditions
- RupturePeritonitisAbdominal AbscessAbdomen, AcuteAbdominal PainAppendicitisInfectionIntestinal PerforationIleusAbscess, Intra-Abdominal
- Interventions
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT01110382
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 716
- Registration Number
- NCT01106651
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 344
- Registration Number
- NCT01106690
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 469
- Registration Number
- NCT01106625
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1284
- Registration Number
- NCT01106677
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT01090427
© Copyright 2025. All Rights Reserved by MedPath